334 related articles for article (PubMed ID: 28797123)
21. Xanthine oxidoreductase activity is correlated with hepatic steatosis.
Yagi C; Kusunoki Y; Tsunoda T; Murase T; Nakamura T; Osugi K; Ohigashi M; Morimoto A; Miyoshi A; Kakutani-Hatayama M; Kosaka-Hamamoto K; Kadoya M; Konishi K; Shoji T; Koyama H
Sci Rep; 2022 Jul; 12(1):12282. PubMed ID: 35854080
[TBL] [Abstract][Full Text] [Related]
22. Differential regulation of hypoxanthine and xanthine by obesity in a general population.
Furuhashi M; Koyama M; Higashiura Y; Murase T; Nakamura T; Matsumoto M; Sakai A; Ohnishi H; Tanaka M; Saitoh S; Moniwa N; Shimamoto K; Miura T
J Diabetes Investig; 2020 Jul; 11(4):878-887. PubMed ID: 31916414
[TBL] [Abstract][Full Text] [Related]
23. Relationship between Xanthine Oxidoreductase Redox and Oxidative Stress among Chronic Kidney Disease Patients.
Terawaki H; Hayashi T; Murase T; Iijima R; Waki K; Tani Y; Nakamura T; Yoshimura K; Uchida S; Kazama JJ
Oxid Med Cell Longev; 2018; 2018():9714710. PubMed ID: 30116501
[TBL] [Abstract][Full Text] [Related]
24. Xanthine oxidoreductase activity in marathon runners: potential implications for marathon-induced acute kidney injury.
Kosaki K; Kumamoto S; Tokinoya K; Yoshida Y; Sugaya T; Murase T; Akari S; Nakamura T; Nabekura Y; Takekoshi K; Maeda S
J Appl Physiol (1985); 2022 Jul; 133(1):1-10. PubMed ID: 35608201
[TBL] [Abstract][Full Text] [Related]
25. Increased plasma xanthine oxidoreductase activity deteriorates coronary artery spasm.
Watanabe K; Shishido T; Otaki Y; Watanabe T; Sugai T; Toshima T; Takahashi T; Yokoyama M; Kinoshita D; Murase T; Nakamura T; Wanezaki M; Tamura H; Nishiyama S; Takahashi H; Arimoto T; Yamauchi S; Yamanaka T; Miyamoto T; Kubota I; Watanabe M
Heart Vessels; 2019 Jan; 34(1):1-8. PubMed ID: 29936631
[TBL] [Abstract][Full Text] [Related]
26. Serum uric acid is associated with left ventricular hypertrophy independent of serum parathyroid hormone in male cardiac patients.
Fujita S; Okamoto Y; Shibata K; Morita H; Ito T; Sohmiya K; Hoshiga M; Ishizaka N
PLoS One; 2013; 8(12):e82735. PubMed ID: 24340056
[TBL] [Abstract][Full Text] [Related]
27. Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction.
Watanabe K; Watanabe T; Otaki Y; Shishido T; Murase T; Nakamura T; Kato S; Tamura H; Nishiyama S; Takahashi H; Arimoto T; Watanabe M
ESC Heart Fail; 2020 Aug; 7(4):1735-1743. PubMed ID: 32432414
[TBL] [Abstract][Full Text] [Related]
28. Diurnal Variations in Serum Uric Acid, Xanthine, and Xanthine Oxidoreductase Activity in Male Patients with Coronary Artery Disease.
Shimizu M; Naito R; Sato A; Ishiwata S; Yatsu S; Shitara J; Matsumoto H; Murata A; Kato T; Suda S; Hiki M; Kuwabara M; Murase T; Nakamura T; Kasai T
Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892555
[TBL] [Abstract][Full Text] [Related]
29. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of plasma xanthine oxidoreductase activity in patients with heart failure with atrial fibrillation.
Watanabe K; Arimoto T; Watanabe T; Otaki Y; Murase T; Nakamura T; Kobayashi Y; Aono T; Saito Y; Koyama K; Hashimoto N; Kutsuzawa D; Kato S; Tamura H; Nishiyama S; Takahashi H; Watanabe M
J Cardiol; 2023 May; 81(5):469-475. PubMed ID: 36822544
[TBL] [Abstract][Full Text] [Related]
31. Serum cystatin C level is associated with left atrial enlargement, left ventricular hypertrophy and impaired left ventricular relaxation in patients with stage 2 or 3 chronic kidney disease.
Sakuragi S; Ichikawa K; Yamada K; Tanimoto M; Miki T; Otsuka H; Yamamoto K; Kawamoto K; Katayama Y; Tanakaya M; Ito H
Int J Cardiol; 2015; 190():287-92. PubMed ID: 25932809
[TBL] [Abstract][Full Text] [Related]
32. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Furuhashi M
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
[TBL] [Abstract][Full Text] [Related]
33. Association between Plasma Xanthine Oxidoreductase Activity and the Renal Function in a General Japanese Population: The Tohoku Medical Megabank Community-Based Cohort Study.
Taguchi S; Nasu T; Satoh M; Kotozaki Y; Tanno K; Tanaka F; Asahi K; Ohmomo H; Kikuchi H; Kobayashi T; Morino Y; Shimizu A; Sobue K; Sasaki M
Kidney Blood Press Res; 2022; 47(12):722-728. PubMed ID: 36318900
[TBL] [Abstract][Full Text] [Related]
34. Purine-Induced IFN-γ Promotes Uric Acid Production by Upregulating Xanthine Oxidoreductase Expression.
Wang H; Xie L; Song X; Wang J; Li X; Lin Z; Su T; Liang B; Huang D
Front Immunol; 2022; 13():773001. PubMed ID: 35154100
[TBL] [Abstract][Full Text] [Related]
35. Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats.
Laakso JT; Teräväinen TL; Martelin E; Vaskonen T; Lapatto R
J Hypertens; 2004 Jul; 22(7):1333-40. PubMed ID: 15201549
[TBL] [Abstract][Full Text] [Related]
36. Low-flow severe aortic stenosis with preserved ejection fraction, N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiovascular remodeling.
Mizia-Stec K; Adamczyk T; Mizia M; Haberka M; Gasior Z; Trusz-Gluza M; Tendera M
J Heart Valve Dis; 2011 May; 20(3):301-10. PubMed ID: 21714421
[TBL] [Abstract][Full Text] [Related]
37. Increased plasma XOR activity induced by NAFLD/NASH and its possible involvement in vascular neointimal proliferation.
Kawachi Y; Fujishima Y; Nishizawa H; Nakamura T; Akari S; Murase T; Saito T; Miyazaki Y; Nagao H; Fukuda S; Kita S; Katakami N; Doki Y; Maeda N; Shimomura I
JCI Insight; 2021 Sep; 6(17):. PubMed ID: 34494551
[TBL] [Abstract][Full Text] [Related]
38. Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry.
Yoshida S; Kurajoh M; Fukumoto S; Murase T; Nakamura T; Yoshida H; Hirata K; Inaba M; Emoto M
Sci Rep; 2020 Mar; 10(1):4437. PubMed ID: 32157204
[TBL] [Abstract][Full Text] [Related]
39. Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care.
Okazaki H; Shirakabe A; Matsushita M; Shibata Y; Sawatani T; Uchiyama S; Tani K; Murase T; Nakamura T; Takayasu T; Asano M; Kobayashi N; Hata N; Asai K; Shimizu W
ESC Heart Fail; 2019 Apr; 6(2):336-343. PubMed ID: 30620450
[TBL] [Abstract][Full Text] [Related]
40. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.
Berry CE; Hare JM
J Physiol; 2004 Mar; 555(Pt 3):589-606. PubMed ID: 14694147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
